Theravance 生物製藥公司
DE ˙ DB ˙ KYG8807B1068
€13.60 ↑0.30 (2.26%)
2026-06-04
分享價格
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership409,435 shares
Latest Disclosed Value $ 6,645,130
Invesco Ltd. reports 130.09% increase in ownership of 0TB / Theravance Biopharma, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 409,435 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $5,404,542 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 177,946 shares of Theravance Biopharma, Inc.. This represents a change in shares of 130.09% during the quarter. The current value of the position is $5,568,316 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 409,435 231,489 130.09 6,645 99.61 0.0001
2026-02-19 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 177,946 153,306 622.18 3,329 827.30 0.0005
2025-11-13 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,640 -684 -2.70 360 28.67 0.0001
2025-08-13 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 25,324 2,789 12.38 279 38.81 0.0000
2025-05-12 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 22,535 -23,515 -51.06 201 -53.58 0.0000
2025-02-13 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 46,050 1,576 3.54 433 20.95 0.0001
2024-11-12 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 44,474 351 0.80 358 -4.28 0.0001
2024-08-13 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 44,123 -81,778 -64.95 374 -66.87 0.0001
2024-05-14 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 125,901 61,215 94.63 1,129 55.30 0.0002
2024-02-13 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 64,686 -39,695 -38.03 727 -19.22 0.0002
2023-11-13 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 104,381 51,530 97.50 901 64.53 0.0002
2023-08-11 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 52,851 349 0.66 547 -3.87 0.0001
2023-05-12 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 52,502 23,900 83.56 570 77.81 0.0002
2023-02-13 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 28,602 -496 -1.70 321 8.11 0.0001
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 29,098 2,817 10.72 296 24.37 0.0001
2022-08-15 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 26,281 373 1.44 238 -4.03 0.0001
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 25,908 179 0.70 248 -12.68 0.0001
2022-02-14 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 25,729 -1,523 -5.59 284 40.59 0.0001
2021-11-15 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 27,252 5,440 24.94 202 -36.28 0.0001
2021-08-17 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 21,812 9,508 77.28 317 26.29 0.0001
2021-05-17 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 12,304 2,271 22.64 251 40.22 0.0001
2021-02-16 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 10,033 10,033 -18.46 179 -28.69 0.0001
2020-08-14 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -25,408 -100.00 0 -100.00
2020-05-15 2020-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 25,408 25,408 587 0.0002
2019-08-14 2019-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 0 -13,190 -100.00 0 -100.00
2019-05-15 2019-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 13,190 -11,788 -47.19 299 -53.21 0.0001
2019-02-14 2018-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 24,978 -926 -3.57 639 -24.47 0.0002
2018-11-14 2018-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 25,904 3,700 16.66 846 67.86 0.0003
2018-08-14 2018-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 22,204 10,695 92.93 504 80.65 0.0002
2018-05-15 2018-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 11,509 4,198 57.42 279 36.76 0.0001
2018-02-14 2017-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 7,311 -49,549 -87.14 204 -89.52 0.0001
2017-11-14 2017-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 56,860 50,331 770.88 1,947 648.85 0.0007
2017-08-14 2017-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 6,529 -23 -0.35 260 7.88 0.0001
2017-05-15 2017-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 6,552 -36,859 -84.91 241 -82.59 0.0001
2017-02-14 2016-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 43,411 -46,741 -51.85 1,384 -57.64 0.0005
2016-11-14 2016-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 90,152 90,152 107.67 3,267 136.05 0.0011
2015-11-16 2015-09-30 13F THERAVANCE BIOPHARMA COMMON G8807B106 0 -373 -100.00 0 -100.00
2015-08-14 2015-06-30 13F THERAVANCE BIOPHARMA COMMON G8807B106 373 373 5 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.